Replies to post #425906 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Ignorance is Yours

You're mistaken about what a biotech's management "knows".

Really? Tell me, why wouldn't Anavex conduct all of the usual aging tests understood and commonly conducted in standardized biological research? Tell us, just why Anavex or it's Non-Disclosure Agreement contractors wouldn't have grown and physiologically assessed the age-status of the cells, organs, and organ systems of Ceanorhabtidis elegans grown in contact with blarcamesine in the growth medium of this standard lab aging-process roundworm?

The normal aging of C. elegans is precisely known. And the organism grows quickly; has a short life span -- all of which makes it the model organism for aging research. Learn that C. elegans is a premier aging research organism:

Age-dependent changes and biomarkers of aging in Caenorhabditis elegans
https://pubmed.ncbi.nlm.nih.gov/30734981/

Caenorhabditis elegans as a Useful Model for Studying Aging Mutations
https://pubmed.ncbi.nlm.nih.gov/33123086/

You are welcome to believe that Anavex has never tested blarcamesine in C. elegans. But Anavex people are not ignorant of the organism and how, at moderate cost, it can reveal antiaging properties of new drugs. Standard bioresearch stuff that you, understandably, are ignorant of.

[kevindenver]

So true. In may ways being a good broker was reeling in your clients excitement and setting expectations accordingly and adjust their position size based on levels of confidence and client risk tolerance.

But, every biotech needs a WGT segment or none of them would get funded.

When investing is done correctly and "safely" within one risk tolerance and financial means, IMO, it's required to have some speculation in the portfolio.